Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Cytosorbents (CTSO) Consolidated Net Income (2016 - 2025)

Cytosorbents' Consolidated Net Income history spans 15 years, with the latest figure at -$6.5 million for Q4 2025.

  • Quarterly results put Consolidated Net Income at -$6.5 million for Q4 2025, down 256.52% from a year ago — trailing twelve months through Dec 2025 was -$15.4 million (down 73.96% YoY), and the annual figure for FY2025 was -$9.2 million, down 2.35%.
  • Consolidated Net Income for Q4 2025 was -$6.5 million at Cytosorbents, down from -$3.2 million in the prior quarter.
  • In the past five years, Consolidated Net Income ranged from a high of $15.3 million in Q4 2023 to a low of -$12.2 million in Q3 2022.
  • The 5-year median for Consolidated Net Income is -$5.4 million (2021), against an average of -$4.4 million.
  • The sharpest move saw Consolidated Net Income plummeted 1273.27% in 2021, then soared 2102.15% in 2023.
  • Year by year, Consolidated Net Income stood at -$9.3 million in 2021, then skyrocketed by 91.77% to -$766126.0 in 2022, then soared by 2102.15% to $15.3 million in 2023, then tumbled by 72.91% to $4.2 million in 2024, then crashed by 256.52% to -$6.5 million in 2025.
  • According to Business Quant data, Consolidated Net Income over the past three periods came in at -$6.5 million, -$3.2 million, and -$4.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.